Evaluation of Low Source of Signal in SCOUT DS

NCT ID: NCT01339637

Last Updated: 2012-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

196 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score (DRS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Impaired Glucose Tolerance Gestational Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Impaired Glucose Tolerance Diabetes Risk Factors Dark Skin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetes risk factors

Very dark skin subjects with with diabetes risk factors

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Dark Skin Tone (Von Luschan chromatic skin color \> 35)
2. Age greater than or equal to 45 years;

OR
3. Age 18 to 44 years and a BMI \> 25 kg/m² with one or more of the following diabetes risk factors:

* Habitually physically inactive (less than 30 minutes of moderate physical activity most, if not all, days of the week)
* Has a first-degree relative with type 2 diabetes
* African American, Latino, Native American, Asian American, Pacific Islander
* Has delivered a baby weighing \> 9 lb or previously diagnosed with gestational diabetes
* Hypertension (≥140/≥ 90 mmHg) or being treated for hypertension
* HDL cholesterol level \< 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
* Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
* Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 years
* Conditions associated with insulin resistance such as severe obesity or acanthosis nigricans
* History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease

Exclusion Criteria

* Prior participation under VeraLight protocols: VL-2710, VL-2711 or VL-2712
* Under 18 years of age
* Receiving investigational treatments in the past 14 days
* Psychosocial issues that interfere with an ability to follow study procedures
* Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
* Diagnosed with any type of diabetes, including type 1 or 2
* Taking glucose lowering medications
* Known to be pregnant
* Receiving dialysis or having known renal compromise
* Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
* Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded
* Current chemotherapy, or chemotherapy within the past 12 months
* Receiving medications that fluoresce\*
* Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
* Known to have, or at risk for, sensitivity to skin lotions or shaving (creams, lotions, soap, shaving cream)
* Prior bariatric surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VeraLight, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John Maynard, MS

Role: STUDY_DIRECTOR

VeraLight, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Radiant Research

Birmingham, Alabama, United States

Site Status

Radiant Research

Atlanta, Georgia, United States

Site Status

Radiant Research

Chicago, Illinois, United States

Site Status

Accelovance

Rockville, Maryland, United States

Site Status

Radiant Research

Kansas City, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VL-2718

Identifier Type: -

Identifier Source: org_study_id